{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:07Z","timestamp":1791304327654,"version":"4.3.1"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T00:00:00Z","timestamp":1465776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The development of vitiligo during treatment with biological agents is an unusual event and only a few isolated cases have been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe the clinical characteristics and evolution of patients developing new\u2010onset vitiligo following initiation of a biological agent for chronic inflammatory disease; and also to report the clinical course of pre\u2010existing vitiligo under biological therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This nationwide multicentre, retrospective study, carried out between July 2013 and January 2015, describes the characteristics of a large series of 18 patients (psoriasis <jats:italic>N<\/jats:italic> = 8, inflammatory rheumatic diseases <jats:italic>N<\/jats:italic> = 8, ulcerative colitis <jats:italic>N<\/jats:italic> = 1, uveitis <jats:italic>N<\/jats:italic> = 1) who developed new\u2010onset vitiligo while receiving a biological agent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u03b1 inhibitors were the most common biological agent involved (13\/18) while anti\u2010<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201012\/23 and anti\u2010<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017 agents or abatacept were less common (4\/18 and 1\/18 respectively). Mean duration of biological agent exposure before vitiligo onset was 13.9 \u00b1 16.5 months. Outcome was favourable for most patients (15\/17) while maintaining the biological agent. Data were also collected for 18 patients (psoriasis <jats:italic>N<\/jats:italic> = 5, inflammatory rheumatic diseases <jats:italic>N<\/jats:italic> = 10, inflammatory bowel diseases <jats:italic>N<\/jats:italic> = 2, <jats:styled-content style=\"fixed-case\">SAPHO <\/jats:styled-content><jats:italic>N<\/jats:italic> = 1) who had pre\u2010existing vitiligo when treatment with a biological agent started (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u03b1 inhibitors <jats:italic>N<\/jats:italic> = 15, ustekinumab <jats:italic>N<\/jats:italic> = 1, rituximab <jats:italic>N<\/jats:italic> = 1, tocilizumab <jats:italic>N<\/jats:italic> = 1). Vitiligo progressed in seven patients and was stable or improved in eight cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Vitiligo may thus emerge and\/or progress during treatment with various biological agents, mainly <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u03b1 inhibitors and could be a new paradoxical skin reaction. <jats:italic>De novo<\/jats:italic> vitiligo displays a favourable outcome when maintaining the biological agent, whereas the prognosis seems worse in cases of pre\u2010existing vitiligo.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.13759","type":"journal-article","created":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T05:22:57Z","timestamp":1465795377000},"page":"181-186","source":"Crossref","is-referenced-by-count":83,"title":["New\u2010onset vitiligo and progression of pre\u2010existing vitiligo during treatment with biological agents in chronic inflammatory diseases"],"prefix":"10.1111","volume":"31","author":[{"given":"L.","family":"M\u00e9ry\u2010Bossard","sequence":"first","affiliation":[{"name":"D\u00e9partement de dermatologie CH Fran\u00e7ois Quesnay Mantes\u2010la\u2010Jolie France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bagny","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine interne et dermatologie CHU Felix Guyon Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Chaby","sequence":"additional","affiliation":[{"name":"D\u00e9partement de dermatologie CHU Amiens Picardie Site Nord Amiens France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Khemis","sequence":"additional","affiliation":[{"name":"D\u00e9partement de dermatologie CHU Archet 2 Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Maccari","sequence":"additional","affiliation":[{"name":"D\u00e9partement de dermatologie HIA B\u00e9gin Saint\u2010Mand\u00e9 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Marotte","sequence":"additional","affiliation":[{"name":"D\u00e9partement de rhumatologie CHU Saint\u2010Etienne H\u00f4pital Nord Saint Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Perrot","sequence":"additional","affiliation":[{"name":"D\u00e9partement de dermatologie CHU Saint Etienne H\u00f4pital Nord Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Reguiai","sequence":"additional","affiliation":[{"name":"D\u00e9partement de dermatologie CHU Reims Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Sigal","sequence":"additional","affiliation":[{"name":"D\u00e9partement de dermatologie CH Victor Dupouy Argenteuil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Avenel\u2010Audran","sequence":"additional","affiliation":[{"name":"D\u00e9partement de dermatologie CHU Angers Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Boy\u00e9","sequence":"additional","affiliation":[{"name":"D\u00e9partement de dermatologie HIA Sainte\u2010Anne Toulon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grasland","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine interne AP\u2010HP H\u00f4pital Louis Mourier Colombes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gillard","sequence":"additional","affiliation":[{"name":"D\u00e9partement de rhumatologie CHT Jura Sud Lons le Saulnier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Jullien","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie CHU Edouard Herriot Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Toussirot","sequence":"additional","affiliation":[{"name":"Centre d'investigation clinique bioth\u00e9rapie INSERM CIC\u20101431 FHU INCREASE Rhumatologie CHRU Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2009.12.003"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2013(09)03"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.10.060"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.04.003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0804388"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000081494"},{"key":"e_1_2_7_8_1","first-page":"217","article-title":"New\u2010onset vitiligo during long\u2010term, stable infliximab treatment of pityriasis rubra pilaris","volume":"12","author":"Mattox AR","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142887"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajg.2011.03.001"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740902922612"},{"key":"e_1_2_7_12_1","first-page":"801","article-title":"Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab","volume":"140","author":"Tousssirot E","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000324619"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.061"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14016"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2011.560913"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12460991"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700900"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00688.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2008.12.033"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000102044"},{"key":"e_1_2_7_22_1","first-page":"534","article-title":"Treatment of generalized vitiligo with anti\u2010TNF\u2010\u03b1 agents","volume":"11","author":"Alghamdi KM","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000112932"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.540"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2002.1o049.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2080"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12661"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.8.750"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.6.561"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1520"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061592"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02744.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354607"},{"key":"e_1_2_7_34_1","first-page":"313","article-title":"Association between vitiligo and spondyloarthritis","volume":"28","author":"Padula A","year":"2001","journal-title":"J Rheumatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13759","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T14:30:15Z","timestamp":1694874615000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,13]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/jdv.13759"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13759","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,13]]}}}